Genmab A/S (GMAB) — AI Analysis & Mentions

Genmab stands out because it reported positive Phase 3 trial results for epcoritamab in lymphoma, with statistically significant improvement in progression-free survival. The company also showed 21% revenue growth and strong gross profit margins, and the data says it may be undervalued. For long-term investors, this is the kind of business progress that matters more than daily stock moves.